$NAYA
Stock $naya

$naya Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031917 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue		$1.837M
YoY Change		481.38%
Cost Of Revenue		$861.6K
YoY Change		265.55%
Gross Profit		$974.9K
YoY Change		1115.8%
Gross Profit Margin		53.08%
Selling, General & Admin		$2.648M
YoY Change		29.61%
% of Gross Profit		271.56%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$25.96K
YoY Change		31.76%
% of Gross Profit		2.66%
Operating Expenses		$2.648M
YoY Change		11.15%
Operating Profit		-$1.903M
YoY Change		-7.89%
Interest Expense		-$351.8K
YoY Change		-300.79%
% of Operating Profit
Other Income/Expense, Net		-$342.3K
YoY Change		99.37%
Pretax Income		-$2.245M
YoY Change		0.34%
Income Tax
% Of Pretax Income
Net Earnings		-$2.245M
YoY Change		0.21%
Net Earnings / Revenue		-122.25%
Basic Earnings Per Share		-$0.62
Diluted Earnings Per Share		-$0.62
COMMON SHARES
Basic Shares Outstanding	3.906M shares	2.743M shares
Diluted Shares Outstanding		3.610M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$942.9K
YoY Change		738.23%
Cash & Equivalents		$942.9K
Short-Term Investments
Other Short-Term Assets		$945.9K
YoY Change		152.42%
Inventory		$250.1K
Prepaid Expenses
Receivables		$257.2K
Other Receivables		$0.00
Total Short-Term Assets		$2.396M
YoY Change		184.53%
LONG-TERM ASSETS
Property, Plant & Equipment		$441.4K
YoY Change		-33.07%
Goodwill		$5.879M
YoY Change
Intangibles		$3.685M
YoY Change
Long-Term Investments		$844.2K
YoY Change		-25.45%
Other Assets
YoY Change
Total Long-Term Assets		$15.64M
YoY Change		169.73%
TOTAL ASSETS
Total Short-Term Assets		$2.396M
Total Long-Term Assets		$15.64M
Total Assets		$18.03M
YoY Change		171.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.378M
YoY Change		28.92%
Accrued Expenses		$883.9K
YoY Change		-38.17%
Deferred Revenue
YoY Change
Short-Term Debt		$880.0K
YoY Change		14.29%
Long-Term Debt Due		$580.1K
YoY Change		119.82%
Total Short-Term Liabilities		$7.989M
YoY Change		78.75%
LONG-TERM LIABILITIES
Long-Term Debt		$1.173M
YoY Change
Other Long-Term Liabilities		$7.507M
YoY Change		93.8%
Total Long-Term Liabilities		$8.679M
YoY Change		124.08%
TOTAL LIABILITIES
Total Short-Term Liabilities		$7.989M
Total Long-Term Liabilities		$8.679M
Total Liabilities		$16.67M
YoY Change		99.75%
SHAREHOLDERS EQUITY
Retained Earnings		-$61.90M
YoY Change		13.37%
Common Stock		$55.77M
YoY Change		5.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$1.364M
YoY Change
Total Liabilities & Shareholders Equity		$18.03M
YoY Change		171.61%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income		-$2.245M
YoY Change		0.21%
Depreciation, Depletion And Amortization		$25.96K
YoY Change		31.76%
Cash From Operating Activities		-$1.456M
YoY Change		-11.48%
INVESTING ACTIVITIES
Capital Expenditures		$55.13K
YoY Change		-78.92%
Acquisitions
YoY Change
Other Investing Activities		$50.00K
YoY Change
Cash From Investing Activities		-$5.130K
YoY Change		-98.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.929M
YoY Change		-1235.4%
NET CHANGE
Cash From Operating Activities		-1.456M
Cash From Investing Activities		-5.130K
Cash From Financing Activities		1.929M
Net Change In Cash		467.8K
YoY Change		-122.54%
FREE CASH FLOW
Cash From Operating Activities		-$1.456M
Capital Expenditures		$55.13K
Free Cash Flow		-$1.511M
YoY Change		-20.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001417926
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Entity Registrant Name EntityRegistrantName	INVO Bioscience, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1705494	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39701
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4036208
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5582 Broadcast Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Sarasota
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34240
	dei	City Area Code CityAreaCode	(978)
	dei	Local Phone Number LocalPhoneNumber	878-9505
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	INVO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3906072	shares
CY2024Q2	us-gaap	Cash Cash	942934	usd
CY2023Q4	us-gaap	Cash Cash	232424	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	257210	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	140550	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	250066	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	264507	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	945853	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	622294	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2396063	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1259775	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	441365	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	826418	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2614466	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5740929	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3684681	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4093431	usd
CY2024Q2	us-gaap	Goodwill Goodwill	5878986	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5878986	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	844198	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	916248	usd
CY2024Q2	INVO	Investment In Affiliates Subsidiaries Associates And Joint Ventures InvestmentInAffiliatesSubsidiariesAssociatesAndJointVentures	2172000	usd
CY2023Q4	INVO	Investment In Affiliates Subsidiaries Associates And Joint Ventures InvestmentInAffiliatesSubsidiariesAssociatesAndJointVentures	2172000	usd
CY2024Q2	us-gaap	Assets Assets	18031759	usd
CY2023Q4	us-gaap	Assets Assets	20887787	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2378099	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2330381	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	646838	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	722251	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2024Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
CY2023Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	INVO	Common Stock Issued Upon Note Payable And Accrued CommonStockIssuedUponNotePayableAndAccrued		usd
	INVO	Deemed Dividend DeemedDividend		usd
	INVO	Fair Value Of Shares Issued Upon Conversion Of Debt FairValueOfSharesIssuedUponConversionOfDebt		usd
	INVO	Initial Right Of Use Asset And Lease Liability InitialRightOfUseAssetAndLeaseLiability		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	INVO	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023Q4	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsOutstanding		usd
	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsGranted		usd
	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsExercised		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	INVO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Forfeiture ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsForfeiture		usd
CY2024Q2	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Options Aggregate Intrinsic Value Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsAggregateIntrinsicValueWarrantsOutstanding		usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	416745	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	408769	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	237030	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	397554	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2500000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2500000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	350000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	350000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7988798	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8218875	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1172902	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1253997	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2506543	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5522090	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5000000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5000000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	16668243	usd
CY2023Q4	us-gaap	Liabilities Liabilities	19994962	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3864072	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3864072	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2492531	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2492531	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	386	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	249	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55767189	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	52710721	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61910463	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57818145	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1363516	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	892825	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18031759	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20887787	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1836597	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	315902	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3412883	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	663927	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	861648	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	235714	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1711882	usd
	us-gaap	Cost Of Revenue CostOfRevenue	466719	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2647524	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2042609	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4088110	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4373443	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83850	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4880	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	157370	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	230338	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19705	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	457298	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38792	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	3739510	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	2381879	usd
	us-gaap	Costs And Expenses CostsAndExpenses	6262170	usd
	us-gaap	Costs And Expenses CostsAndExpenses	5036324	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1902913	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2065977	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2849287	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4372397	usd
CY2024Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	17846	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3788	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	17950	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-23947	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	50000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-511663	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	94551	usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40491	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40491	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	369612	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	175192	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	550907	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	391781	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-265	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-342257	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-171669	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-990560	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-416128	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2245170	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2237646	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3839847	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4788525	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2865	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1836	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2865	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2245170	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2240511	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3841683	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4791390	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.07
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.07
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3609812	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	732255	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3072877	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	677684	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3609812	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	732255	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3072877	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	677684	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-977612	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	46503	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	149900	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2708642	usd
CY2023Q1	INVO	Stock Issued During Period Value Common Stock Issued With Notes Payable StockIssuedDuringPeriodValueCommonStockIssuedWithNotesPayable	56313	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2376	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	325834	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	327389	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2550879	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	88466	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5062	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	94276	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20297	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	326916	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2240511	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	892825	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	92	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	142450	usd
CY2024Q1	INVO	Stock Issued During Period Value Preferred Stock New Issues StockIssuedDuringPeriodValuePreferredStockNewIssues	500000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	71301	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1596513	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	10155	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	10155	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	61	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	59998	usd
CY2024Q2	INVO	Stock Issued During Period Value Preferred Stock New Issues StockIssuedDuringPeriodValuePreferredStockNewIssues	1006404	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	165131	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	188755	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	40491	usd
CY2024Q2	INVO	Adjustments To Additional Paid In Capital Warrants Issued AdjustmentsToAdditionalPaidInCapitalWarrantsIssued	971012	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	197033	usd
CY2024Q2	INVO	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	900611	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	69035	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2245170	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1363516	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1363516	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3841683	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4791390	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1173460	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	244176	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	153	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	51565	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	140336	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	652750	usd
	INVO	Noncash Compensation For Services NoncashCompensationForServices	90000	usd
	INVO	Noncash Compensation For Services NoncashCompensationForServices	90000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	349010	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	301098	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	17950	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-23947	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-40491	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-511663	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	94551	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	457298	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38792	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	116660	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2241	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14441	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16416	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	469479	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	184513	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	35435	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	432654	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-75413	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	256158	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7976	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	41311	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	10080	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1829	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	69179	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	62938	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1716214	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2792860	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104829	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261505	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	75590	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	8447	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29239	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-269952	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	442500	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	714000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	165131	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2728938	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1506404	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	900611	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2375	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	558683	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	360151	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2455963	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3085162	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	710510	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22350	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	232424	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90135	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	942934	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112485	usd
	us-gaap	Interest Paid Net InterestPaidNet	108513	usd
	us-gaap	Interest Paid Net InterestPaidNet	5720	usd
	INVO	Common Stock Issued Upon Note Payable And Accrued CommonStockIssuedUponNotePayableAndAccrued	197033	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	188755	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	327390	usd
	INVO	Deemed Dividend DeemedDividend	250635	usd
	INVO	Fair Value Of Shares Issued Upon Conversion Of Debt FairValueOfSharesIssuedUponConversionOfDebt	197033	usd
	INVO	Initial Right Of Use Asset And Lease Liability InitialRightOfUseAssetAndLeaseLiability	2312892	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zbbfSByGaUo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zdn2oO1m0pYe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zSzanNF0rNg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zoLeV7hei1Pk">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of June 30, 2024, the Company had cash balances in excess of FDIC limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2245170	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2240511	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3841683	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4791390	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3609812	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3609812	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	732255	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	732255	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3072877	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3072877	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	677684	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	677684	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.06
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.07
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6646089	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	524526	shares
	us-gaap	Net Income Loss NetIncomeLoss	-3800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4800000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61900000	usd
	INVO	Net Income Loss Related To Non Cash Expenses NetIncomeLossRelatedToNonCashExpenses	2600000	usd
	INVO	Net Income Loss Related To Non Cash Expenses NetIncomeLossRelatedToNonCashExpenses	1400000	usd
CY2021Q2	INVO	Hurdle Amount HurdleAmount	0	usd
CY2021Q2	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	1.50	pure
	INVO	Investment In Unconsolidated Variable Interest Entities InvestmentInUnconsolidatedVariableInterestEntities	844198	usd
CY2023	INVO	Investment In Unconsolidated Variable Interest Entities InvestmentInUnconsolidatedVariableInterestEntities	916248	usd
CY2024Q2	INVO	Earning Loss From Unconsolidated Variable Interest Entities EarningLossFromUnconsolidatedVariableInterestEntities	17846	usd
CY2023Q2	INVO	Earning Loss From Unconsolidated Variable Interest Entities EarningLossFromUnconsolidatedVariableInterestEntities	3788	usd
	INVO	Earning Loss From Unconsolidated Variable Interest Entities EarningLossFromUnconsolidatedVariableInterestEntities	17950	usd
	INVO	Earning Loss From Unconsolidated Variable Interest Entities EarningLossFromUnconsolidatedVariableInterestEntities	-23947	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	53480	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	53479	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	196586	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	211028	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	250066	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	264507	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	282141	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	233593	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	441365	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	826418	usd
CY2024Q2	us-gaap	Depreciation Depreciation	25963	usd
CY2023Q2	us-gaap	Depreciation Depreciation	19705	usd
	us-gaap	Depreciation Depreciation	48548	usd
	us-gaap	Depreciation Depreciation	38792	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	50000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-511663	usd
CY2024Q2	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	253000	usd
CY2023Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	253000	usd
CY2024Q2	INVO	Finite Lived Noncompetition Agreement FiniteLivedNoncompetitionAgreement	3961000	usd
CY2023Q4	INVO	Finite Lived Noncompetition Agreement FiniteLivedNoncompetitionAgreement	3961000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	5878986	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5878986	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	529319	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	120569	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9563667	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9972417	usd
CY2023Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	34000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	204375	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	408750	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2614466	usd
CY2024Q2	INVO	Right Of Use Assets RightOfUseAssets	2614466	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	237030	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2506543	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2743573	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	235757	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	477947	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	490122	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	480096	usd
CY2024Q2	INVO	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	2329321	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4013243	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1269670	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2743573	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P102M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	94551	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	282101	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	264932	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	2632988	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	2763917	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	17500	shares
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200000	usd
CY2022Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	These notes accrue 10% annual interest accrues from the date of issuance. These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee, and accrued interest.
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	410000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	410000	usd
CY2022Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	310000	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	12.00
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	19375	shares
CY2024Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-12-31
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	40491	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	78443	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.08	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.08	pure
CY2023Q1	us-gaap	Share Price SharePrice	10.40
CY2023Q1	us-gaap	Share Price SharePrice	10.40
CY2023Q1	INVO	Percentage Of Debentures Outstanding PercentageOfDebenturesOutstanding	0.50	pure
CY2023Q1	INVO	Percentage Of Debentures Outstanding PercentageOfDebenturesOutstanding	0.50	pure
CY2024Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	11655	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	17500	shares
	us-gaap	Interest Expense Debt InterestExpenseDebt	40444	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	375422	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6250000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6250000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	106753	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8761	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	31.58
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	97992	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.20
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	88218	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	51.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.036	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0369	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.066	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.149	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1049109	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	140336	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3488620	shares
CY2023Q4	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Warrants ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceWarrants	3.95
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1444812	shares
	INVO	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	1.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	807000	shares
	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Of Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOfWarrantsExercised	1.20
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4126432	shares
CY2024Q2	INVO	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Warrants ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceWarrants	1.79
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.20
CY2024Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	11655	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1836	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2865	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2865	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0	pure
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	5.00
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	INVO	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024Q2	INVO	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-24-031917-index-headers.html	Edgar Link	pending
0001493152-24-031917-index.html	Edgar Link	pending
0001493152-24-031917.txt	Edgar Link	pending
0001493152-24-031917-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10q.htm	Edgar Link	pending
invo-20240630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
invo-20240630_cal.xml	Edgar Link	unprocessable
invo-20240630_def.xml	Edgar Link	unprocessable
invo-20240630_lab.xml	Edgar Link	unprocessable
invo-20240630_pre.xml	Edgar Link	unprocessable
form10q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NAYA
Stock $naya

2024 Q3 Form 10-Q Financial Statement

#000149315224031917 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NAYA Stock $naya

2024 Q3 Form 10-Q Financial Statement

#000149315224031917 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NAYA
Stock $naya